Additional Support - Banner
Support Organizations
Support Organizations
The entities below are independent from and unaffiliated with Daiichi Sankyo, Inc. and Daiichi Sankyo, Inc. does not review or endorse any of the organizations listed below.
Support Organizations
The entities below are independent from and unaffiliated with Daiichi Sankyo, Inc. and Daiichi Sankyo, Inc. does not review or endorse any of the organizations listed below.
VANFLYTA is available only through a restricted program called the VANFLYTA Risk Evaluation and Mitigation Strategy (REMS) due to the risk of QT prolongation, torsades de pointes, and cardiac arrest.
You will receive a VANFLYTA Patient Wallet Card from your healthcare provider. Carry the VANFLYTA Patient Wallet Card with you at all times and show it to all of your healthcare providers. The VANFLYTA Patient Wallet Card lists signs and symptoms of QT prolongation and torsades de pointes.
Get medical help right away if you develop any of the signs and symptoms listed on the VANFLYTA Patient Wallet Card. You may need to be treated in a hospital.
See “What are the possible side effects of VANFLYTA?” for more information about side effects.
VANFLYTA is a prescription medicine used in combination with certain chemotherapy medicines and alone as maintenance therapy to treat adults with newly diagnosed acute myeloid leukemia (AML) with a FLT3-ITD mutation.
Your healthcare provider will perform a test to make sure that VANFLYTA is right for you.
VANFLYTA is not for use alone as maintenance therapy after a hematopoietic stem cell transplant.
It is not known if VANFLYTA is safe and effective in children.
Do not take VANFLYTA if you have very low potassium, very low magnesium, long QT syndrome, or a history of ventricular arrhythmias or torsades de pointes.
Before you take VANFLYTA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VANFLYTA and other medicines may affect each other causing side effects.
Especially tell your healthcare provider if you take St. John’s wort. You should not take St. John’s wort during treatment with VANFLYTA.
VANFLYTA may cause serious side effects, including:
The most common side effects of VANFLYTA include:
Your healthcare provider will do blood tests and ECGs before you start and during treatment with VANFLYTA. Your healthcare provider may tell you to decrease your dose, temporarily stop, or permanently stop taking VANFLYTA if you develop certain side effects during treatment with VANFLYTA.
VANFLYTA may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility.
These are not all the possible side effects of VANFLYTA. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Please see Full Prescribing Information, including Boxed WARNINGS, and Medication Guide.
This site is intended only for U.S. healthcare professionals and/or healthcare professionals involved in healthcare reimbursement.